clinical trial · NCT00515437
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC·phase2·completed·n = 54
DroolingBotulinum Toxin Type B (Myobloc)Matched placebo to Myobloc
brief summary
To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients
started
Jul 1, 2007
primary completion
Jun 1, 2008
completion
Sep 1, 2008
last updated
Apr 21, 2026
detailed description
This is a multi-center, outpatient, double-blind, placebo-controlled, single treatment, sequential dose escalation study designed to evaluate the safety, tolerability and preliminary efficacy of single doses of MYOBLOC versus placebo for the treatment of sialorrhea in Parkinson's disease patients, lasting approximately 20 weeks.
official title
A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol